Literature DB >> 15009003

Early postoperative indicators of late outcome in acromegalic patients.

Jun A Takahashi1, Akira Shimatsu, Kazuwa Nakao, Nobuo Hashimoto.   

Abstract

OBJECTIVE: According to current criteria, normalised serum IGF-1 and glucose-suppressed GH < 1 ng/ml are indicators of biochemical cure in acromegalic patients. We performed a retrospective study to assess whether the attainment of these values in the early postoperative period was predictive of future IGF-1 normalisation and disease inactivity. PATIENTS, MEASUREMENTS AND
RESULTS: Between 1978 and 1999, 78 acromegalic patients underwent resection for pituitary adenomas. At the end of the mean follow-up period of 7 years, 43 (55.1%) showed normalised IGF-1 levels and no disease activity. In 51 cases, both IGF-1 and glucose-suppressed GH were examined within the first postoperative month. Of this group, all 19 patients who had early glucose-suppressed GH < 1 ng/ml and were treated by surgery alone maintained normal IGF-1 levels throughout the follow-up; four of them demonstrated delayed (i.e. more than 30 days after the operation) IGF-1 normalisation. In 19 patients with early glucose-suppressed GH levels of 1-4 ng/ml, seven of 11 patients with early normalised IGF-1 and two of eight patients with early IGF-1 elevation manifested eventual IGF-1 normalisation. However, none of the 13 patients with early glucose-suppressed GH > 4 ng/ml attained IGF-1 normalisation. Both univariate and multivariate analyses indicated that early glucose-suppressed GH was a significant factor for predicting late normalised IGF-1; the cut-off value was 1.5 ng/ml (sensitivity: 0.97; specificity: 0.75; odds ratio: 90).
CONCLUSION: The attainment of both normalised IGF-1 and glucose-suppressed GH < 1 ng/ml, even during the early postoperative period, suggests absolute cure in acromegalic patients. However, even in patients who do not meet both criteria within the first postoperative month, glucose-suppressed GH < 1.5 ng/ml, or glucose-suppressed GH < 4 ng/ml coupled with early IGF-1 normalisation indicate the possibility of eventual normalisation of IGF-1 and disease inactivity without adjuvant therapy. These postoperative parameters may be useful for assessing the desirability of further treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009003     DOI: 10.1046/j.1365-2265.2003.01900.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly.

Authors:  Ximene Antunes; Nina Ventura; Gustavo Bittencourt Camilo; Luiz Eduardo Wildemberg; Andre Guasti; Paulo José M Pereira; Aline Helen Silva Camacho; Leila Chimelli; Paulo Niemeyer; Mônica R Gadelha; Leandro Kasuki
Journal:  Endocrine       Date:  2018-04-06       Impact factor: 3.633

Review 2.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

4.  Improvement of insulin resistance following transsphenoidal surgery in patients with acromegaly: correlation with serum IGF-I levels.

Authors:  K Mori; Y Iwasaki; Y Kawasaki-Ogita; S Honjo; Y Hamamoto; H Tatsuoka; K Fujimoto; H Ikeda; Y Wada; Y Takahashi; J Takahashi; H Koshiyama
Journal:  J Endocrinol Invest       Date:  2013-05-10       Impact factor: 4.256

5.  Surgical management of growth hormone-secreting pituitary adenomas: A retrospective analysis of 33 patients.

Authors:  Yong Zheng; Dong-Ming Chen; Yan Wang; Rong-Kang Mai; Zi-Feng Zhu
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.889

6.  Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?

Authors:  Lena Rass; Amir-Hossein Rahvar; Jakob Matschke; Wolfgang Saeger; Thomas Renné; Jens Aberle; Jörg Flitsch; Roman Rotermund
Journal:  Hormones (Athens)       Date:  2021-10-21       Impact factor: 2.885

7.  Surgical management of acromegaly: Long term functional outcome analysis and assessment of recurrent/residual disease.

Authors:  Deepu Banerji; Nitu K Das; Siddhiraj Sharma; Yogesh Jindal; Vijendra K Jain; Sanjay Behari
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep

8.  First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence.

Authors:  V Cambria; G Beccuti; N Prencipe; F Penner; V Gasco; F Gatti; M Romanisio; M Caputo; E Ghigo; F Zenga; S Grottoli
Journal:  J Endocrinol Invest       Date:  2021-04-10       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.